GleamWall
中文EN

CYDY CytoDyn Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1175680 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-171.6%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-351.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets614.7%
Debt / equity—
Current ratio0.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-212.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-08-312026Q4*2026-05-312026Q32026-02-282026Q22025-11-302026Q12025-08-312025Q4*2025-05-312025Q32025-02-282025Q22024-11-30
Income statement
Revenue————————
SG&A expense$2.06M$2.28M$1.65M$1.80M$1.71M$1.85M$1.52M$2.30M
Operating income-$6.58M-$5.64M-$6.30M-$21.69M-$4.95M-$5.07M-$4.00M-$3.71M
Pretax income-$19.94M-$9.86M-$4.69M-$22.61M-$5.54M-$5.96M-$4.76M-$4.77M
Income tax$0$0$0$0$0$0$0$0
Net income-$19.94M-$9.86M-$4.69M-$22.61M-$5.54M-$5.96M-$4.76M-$4.77M
EBITDA-$6.56M-$5.63M-$6.30M-$21.68M-$4.94M-$5.06M-$4.00M-$3.70M
EPS (basic)-0.01—0.00-0.020.00—0.000.00
EPS (diluted)-0.01—0.00-0.020.00—0.000.00
Weighted avg. shares (diluted)1.38B—1.28B1.26B1.25B—1.23B1.22B
Balance sheet
Cash & equivalents$16.36M$11.85M$15.65M$4.98M$9.33M$11.90M$16.40M$21.34M
Current assets$18.98M$13.88M$18.44M$8.84M$13.35M$17.88M$20.98M$24.63M
Total assets$19.05M$13.97M$18.50M$8.94M$13.48M$18.05M$21.19M$24.88M
Current liabilities$49.70M$53.73M$50.43M$85.11M$69.42M$70.52M$70.56M$70.63M
Long-term debt$35.81M$38.34M$40.53M$42.17M$43.78M$45.35M$45.84M$46.08M
Total debt$35.81M$38.34M$40.53M$42.17M$43.78M$45.35M$45.84M$46.08M
Total liabilities$117.13M$123.69M$122.78M$128.68M$112.99M$114.09M$114.17M$114.27M
Shareholders' equity-$98.07M-$109.72M-$104.29M-$119.75M-$99.50M-$96.04M-$92.98M-$89.39M
Net debt$19.45M$26.49M$24.88M$37.19M$34.45M$33.45M$29.44M$24.75M
Shares outstanding1.45B1.37B1.36B1.27B1.26B1.25B1.23B1.22B
Cash flow statement
Operating cash flow-$7.73M-$4.93M-$5.52M-$4.35M-$2.45M-$5.66M-$4.96M-$3.59M
Investing cash flow$0———$0———
Financing cash flow$12.23M$1.13M$16.19M$0-$121,000$1.17M$21,000$0
Depreciation & amortization$19,000$4,000$4,000$5,000$4,000$4,000$5,000$4,000
Stock-based compensation$524,000$823,000$445,000$183,000$179,000$599,000$340,000$537,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.